Antitumor activity and efficacy of shorter longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis

Antitumor activity and efficacy of shorter longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis

Background: Neoadjuvant anthracycline-taxane-based chemotherapy (ChT) is a standard of care treatment option for stage II–III breast cancer (BC) patients. However, the optimal duration of neoadjuvant ChT has been poorly investigated so far. Material and methods: We retrospectively retrieved clinical...

Full description

Bibliographic Details
Main Authors: Riccardo Lobefaro, Emma Zattarin, Federico Nichetti, Michele Prisciandaro, Francesca Ligorio, Marta Brambilla, Pierangela Sepe, Francesca Corti, Giorgia Peverelli, Arianna Ottini, Teresa Beninato, Laura Mazzeo, Carmen G. Rea, Gabriella Mariani, Filippo de Braud, Giulia V. Bianchi, Claudio Vernieri, Giuseppe Capri
Format: Article
Language:English
Published: SAGE Publishing 2020-12-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920970081

Internet

https://doi.org/10.1177/1758835920970081

Similar Items